Weekly Top News – Psoriasis– January 20, 2020

January 20, 2020

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
New head-to-head phase 3 data show Skyrizi (risankizumab) superior to Cosentyx (secukinumab) across primary and all ranked secondary endpoints in adults with moderate to severe plaque psoriasis at 52 weeks (PRNewswire) – Jan 14, 2020 – P3, N=327; NCT03478787; Sponsor: AbbVie; “AbbVie…today announced that SKYRIZI™ met both primary and all ranked secondary endpoints, including superiority at week 52, versus Cosentyx® in a head-to-head Phase 3 study….’In this study, SKYRIZI showed superior efficacy compared to Cosentyx in helping patients achieve and maintain high levels of skin clearance at week 52’….Current safety data available demonstrated that the safety profile of SKYRIZI was consistent with that observed in previously reported studies, with no new safety signals observed through week 52.


bimekizumab (UCB4940) / UCB
Bimekizumab clinical trial estimate: Detailed data from P3 trials BE VIVID (NCT03370133) and BE READY (NCT03410992) for moderate to severe plaque psoriasis at AAD (March 20-24, 2020) – Jan 17, 2020 – A subscription to Thomson ONE is required to gain full access to report 68594462; Page no: 206; REPORT TITLE: “EU Pharma & Biotech: Sector set to top the medal table in an Olympic year”; AUTHOR: Vosser, Richard, et al; DATE: 01/06/2020


Stelara (ustekinumab) / J&J; bimekizumab (UCB4940) / UCB
BE VIVID: A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (clinicaltrials.gov) – Jan 18, 2020 – P3; N=570; Completed; Sponsor: UCB Biopharma S.P.R.L.; Active, not recruiting –> Completed


Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
IMMpact2: A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (clinicaltrials.gov) – Jan 13, 2020 – P3; N=444; Active, not recruiting; Sponsor: AbbVie; Recruiting –> Active, not recruiting; Trial primary completion date: Jan 2021 –> Jun 2020


Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall
Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE) (clinicaltrials.gov) – Jan 15, 2020 – P4; N=160; Recruiting; Sponsor: Almirall, S.A.

No Comments

Post a Comment